Allogene Therapeutics, Inc.’s ALLO share price has surged by 6.64%, which has investors questioning if this is right time to ...

Analysts at Zacks Research upped their Q1 2025 EPS estimates for shares of Allogene Therapeutics in a research note issued to ...

Equities research analysts at Zacks Research issued their Q1 2027 earnings per share estimates for Allogene Therapeutics in a ...

In a report released today, Sami Corwin from William Blair maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report). The ...

Allogene Therapeutics (ALLO) announced that ALLO-329, an investigational dual-targeted CD19/CD70 allogeneic CAR T, has received three Fast ...

The FDA's fast track designations will facilitate rapid development and expedited review of ALLO's autoimmune disease candidate.

SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. (NASDAQ: ALLO), a $313 million market cap biotechnology firm focusing on allogeneic CAR T therapies, announced today that its investigational CAR ...

SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. (NASDAQ: ALLO), a $313 million market cap biotechnology firm focusing on allogeneic CAR T therapies, announced today that its investigational CAR T ...

(RTTNews) - Clinical-stage biotechnology company Allogene Therapeutics, Inc. (ALLO), Monday announced that ALLO-329, an investigational dual-targeted CD19/CD70 allogeneic CAR T, has received three ...